Imeglyn 1000 Mg (Imeglimin)

Product Overview

Imeglimin 1000 mg tablets are a prescription oral antihyperglycemic medication indicated for the treatment of type 2 diabetes mellitus. Manufactured by Zydus Lifesciences, each strip contains ten film‑coated tablets delivering a consistent 1000 mg dose of the active ingredient imeglimin. The product is packaged for convenience in strengths of 90, 180, or 270 tablets, allowing patients to select a pack size that matches their therapeutic plan. Imeglimin belongs to a class of glucose‑lowering agents that enhance insulin sensitivity and promote glucose excretion without causing hypoglycemia when used as directed. This medication is intended for adult patients who have not achieved adequate glycemic control through diet and exercise alone. The tablets are formulated for once‑daily administration, offering a simple dosing schedule that supports adherence in busy lifestyles. For detailed scientific information, refer to resources such as the National Institutes of Health.

What is Imeglimin

Imeglimin is a novel biguanide‑like compound that acts primarily on the liver and peripheral tissues to reduce hepatic glucose production and improve peripheral insulin action. Unlike traditional biguanides, imeglimin exhibits a unique pharmacokinetic profile that results in a longer duration of action and a lower risk of accumulating in renal tissue. The active molecule is rapidly absorbed after oral administration, reaches peak plasma concentrations within one to two hours, and is eliminated primarily through the biliary route. Its mechanism involves modulation of AMP‑activated protein kinase (AMPK) pathways, which play a central role in cellular energy balance. By enhancing AMPK activity, imeglimin promotes fatty acid oxidation and reduces gluconeogenesis, leading to improved fasting and post‑prandial glucose levels. The drug’s selective tissue targeting helps maintain glucose homeostasis while minimizing systemic exposure.

Uses and Benefits

The primary use of Imeglimin 1000 mg is to lower blood glucose in adults with type 2 diabetes who have not responded adequately to metformin or other first‑line agents. Clinical studies have demonstrated that treatment results in a mean reduction of HbA1c by approximately 1.0% to 1.2% after 24 weeks of therapy, comparable to other oral hypoglycemics but with a distinct safety profile. In addition to glycemic control, imeglimin has been shown to modestly decrease body weight and improve lipid parameters, including triglycerides and high‑density lipoprotein cholesterol. These secondary benefits make it an attractive option for patients with comorbidities such as obesity or dyslipidemia. The medication is also associated with a low incidence of hypoglycemia when used alone or in combination with low‑dose sulfonylureas, offering a safer alternative for patients at risk of glucose fluctuations. Health‑care providers often prescribe imeglimin as part of a comprehensive diabetes management program that includes dietary modifications, physical activity, and regular glucose monitoring.

How It Works

The pharmacological action of imeglimin centers on its ability to activate AMP‑activated protein kinase (AMPK) in hepatic and skeletal muscle cells. AMPK functions as a cellular energy sensor; when activated, it inhibits gluconeogenic enzymes in the liver and stimulates glucose uptake in muscle tissue. This dual effect reduces fasting glucose output and enhances peripheral insulin sensitivity. Additionally, imeglimin slows intestinal absorption of carbohydrates, contributing to lower post‑prandial spikes. The drug’s impact on fatty acid oxidation helps decrease hepatic fat accumulation, which is often linked to insulin resistance. By improving both glucose production and utilization, imeglimin provides a balanced approach to glycemic control that addresses multiple pathophysiological pathways involved in type 2 diabetes. Its mechanism is complementary to that of sulfonylureas and DPP‑4 inhibitors, allowing clinicians to tailor therapy based on patient‑specific needs.

Dosage Guidelines

Patients are advised to take one Imeglimin 1000 mg tablet orally once daily, preferably with the morning meal, to achieve consistent plasma levels throughout the day. The tablet should be swallowed whole with water and should not be crushed or chewed, as this could alter the release characteristics. Dosage adjustments are not routinely required based on renal function unless the patient has severe renal impairment (eGFR <30 mL/min/1.73 m²), in which case the prescribing clinician may consider a reduced frequency. For most individuals, the standard dose provides adequate glycemic control without necessitating titration. However, health‑care providers may increase the dose to a maximum of 2000 mg per day if the initial response is insufficient after an appropriate wash‑out period of at least 12 weeks. It is essential that patients follow the dosing instructions on their prescription label and consult their physician before making any changes. Regular laboratory monitoring of kidney function and liver enzymes is recommended during long‑term therapy to ensure safety.

Side Effects

Like all prescription medicines, Imeglimin may cause adverse effects, although most are mild and transient. The most commonly reported side effects include gastrointestinal discomfort such as nausea, abdominal pain, and diarrhea, which typically resolve within the first few weeks of therapy. Some patients may experience a metallic taste or mild dizziness, particularly during the initial dose adjustment period. Rare but serious adverse reactions can involve hepatic enzyme elevations; therefore, clinicians should obtain baseline liver function tests and repeat them periodically. There have been isolated reports of hypersensitivity reactions, including skin rash and, very rarely, angioedema, which require immediate medical attention. Patients should be instructed to report any persistent or worsening symptoms to their health‑care provider promptly. In the event of severe hypoglycemia, although uncommon with imeglimin monotherapy, patients should treat according to their emergency plan and seek medical care. For a comprehensive list of reported adverse events, see the Drugs.com database.

Warnings and Precautions

Before initiating therapy with Imeglimin, health‑care professionals should assess renal function, as the drug is primarily eliminated through hepatic pathways but requires caution in patients with advanced kidney disease. Concomitant use with other glucose‑lowering agents may increase the risk of hypoglycemia; dose adjustments of the partner medication may be necessary. Patients with a history of liver disease should be monitored for hepatic decompensation, and those with severe hepatic impairment should avoid use. Imeglimin is classified as pregnancy category B, indicating that animal studies have not demonstrated risk to the fetus, but human data are limited; therefore, it should be used during pregnancy only if clearly needed. Breastfeeding is not recommended while taking this medication, as it may pass into milk. Alcohol consumption should be moderated, as excessive intake can affect liver function and glucose control. The U.S. Food and Drug Administration (FDA) provides post‑marketing surveillance data that help monitor safety. Finally, patients should be advised to maintain regular follow‑up appointments to evaluate efficacy, safety, and any emerging side effects.

Frequently Asked Questions

1. What is the recommended starting dose of Imeglimin? The usual starting dose is one 1000 mg tablet taken once daily with food, as prescribed by your physician.
2. Can Imeglimin be taken with other diabetes medications? Yes, it can be combined with metformin or low‑dose sulfonylureas, but your doctor may adjust the partner drug dose to reduce hypoglycemia risk.
3. How long does it take to see improvements in blood sugar levels? Most patients experience a measurable reduction in fasting glucose within two to four weeks, with full HbA1c benefits appearing after three months of consistent use.
4. Is Imeglimin safe for patients with kidney problems? Imeglimin is not primarily cleared by the kidneys, but caution is advised in severe renal impairment; your clinician will evaluate kidney function before prescribing.
5. What should I do if I miss a dose? Take the missed tablet as soon as you remember, unless it is almost time for the next dose; do not double up to make up for a missed tablet.